Ustekinumab

Indication

Ustekinumab for treating moderately to severely active ulcerative colitis (TA 633)

Red

Brand:

Stelara

Nice TA:

633

Commissioning responsibility:

CCG

PbR excluded:

Yes

BNF chapter:

Gastro-intestinal system

Background

1.1 Ustekinumab is recommended as an option for treating moderately to severely active ulcerative colitis in adults when conventional therapy or a biological agent cannot be tolerated, or the disease has responded inadequately or lost response to treatment, only if:

a tumour necrosis factor‑alpha inhibitor has failed (that is the disease has responded inadequately or has lost response to treatment) or
a tumour necrosis factor‑alpha inhibitor cannot be tolerated or is not suitable, and
the company provides ustekinumab at the same price or lower than that agreed with the Commercials Medicines Unit.

Recommendation

LSCMMG Recommendation:

Red

Reason for decision:

Specialist medicine

Supporting documents:

Decisions of Lancashire local decision making groups

BwD	BP	CSR	EL	FW	GP	MB	WL
Red	Red	Red	Red	Red	Red	Red	Red

What do the colours mean?

Last Updated: 13 - Jul - 2020